Q178: Prior Exposure: Potential Study Eligibility (for consented recipients only)

*Additional Forms Come Due
Selecting one of the options below may generate an additional supplemental form.

Question 178: Specify if the recipient received the following (at any time prior to HCT / infusion)

Indicate if the following agent was administered to the patient prior to HCT / infusion:

• Mogamulizumab: A monoclonal antibody used to treat mycosis fungoides or Sezary syndrome (types of cutaneous T-cell lymphoma). It is also being studied in the treatment of other types of cancer.
  

If the recipient did not receive the agent listed above, select None of the above.

Section Updates:

Question Number	Date of Change	Add/Remove/Modify	Description	Reasoning (If applicable)
.	.	.	.	.

Copyright © 2004-2025 The Medical College of Wisconsin, Inc. and NMDP. All Rights Reserved.
CIBMTR® (Center for International Blood and Marrow Transplant Research) is a research collaboration between the Medical College of Wisconsin and NMDP.